Department of Infectious Diseases, Research Institute, International Medical Centre of Japan, Shinjuku, Tokyo, Japan.
Clin Microbiol Infect. 2010 Aug;16(8):1164-8. doi: 10.1111/j.1469-0691.2009.03078.x. Epub 2009 Oct 14.
Thirty-six multidrug-resistant (MDR) Mycobacterium tuberculosis isolates collected in Japan were examined for pyrazinamide susceptibility and pyrazinamidase activity, and analysed by pncA sequencing and a hybridization-based line probe assay (LiPA), which was used to detect pncA mutations for the rapid identification of pyrazinamide-resistant isolates. Pyrazinamide resistance was found in 19 (53%) of them. All pyrazinamide-resistant isolates had no pyrazinamidase activity and at least one mutation in pncA. Among the pncA mutations, 11 had not been previously reported. The results of the LiPA were fully consistent with the DNA sequencing results. A majority of MDR M. tuberculosis isolates in Japan were resistant to pyrazinamide.
在日本收集的 36 株多药耐药（MDR）结核分枝杆菌分离株进行了吡嗪酰胺敏感性和吡嗪酰胺酶活性检测，并通过 pncA 测序和基于杂交的线性探针分析（LiPA）进行了分析，LiPA 用于检测 pncA 突变，以快速鉴定吡嗪酰胺耐药分离株。其中 19 株（53%）存在吡嗪酰胺耐药。所有吡嗪酰胺耐药分离株均无吡嗪酰胺酶活性，并且 pncA 中至少有一个突变。在 pncA 突变中，有 11 种以前没有报道过。LiPA 的结果与 DNA 测序结果完全一致。日本的大多数 MDR 结核分枝杆菌分离株对吡嗪酰胺耐药。
